In this episode of Research Reverb, we're diving into the complexities of transparency in drug development and its surprising impact on innovation. Professor Hanu Tyagi explores the tension between openness and creativity in the pharmaceutical industry.

What if being too transparent is slowing down the next groundbreaking cure? In his research, Professor Tyagi finds that increased transparency in clinical trials has led to a 13.9% shift toward “safer” but less novel drug development strategies—equivalent to falling two years behind on the innovation curve.